Brief: Grand Pharmaceutical Says Phase III Clinical Trial Application Of Drug Itm-11 Accepted By NMPA
14/10/2024 17:03
Oct 14 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* PHASE III CLINICAL TRIAL APPLICATION OF DRUG ITM-11
ACCEPTED BY
CHINA NMPA
Further company coverage: 0512.HK
(Reporting by Archishma Iyer)
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement